Low expression of PDK1 inhibits renal cell carcinoma cell proliferation, migration, invasion and epithelial mesenchymal transition through inhibition of the PI3K-PDK1-Akt pathway.


Journal

Cellular signalling
ISSN: 1873-3913
Titre abrégé: Cell Signal
Pays: England
ID NLM: 8904683

Informations de publication

Date de publication:
04 2019
Historique:
received: 11 07 2018
revised: 16 11 2018
accepted: 19 11 2018
pubmed: 23 11 2018
medline: 16 5 2020
entrez: 23 11 2018
Statut: ppublish

Résumé

As the most commonly occurring form of primary renal tumor, renal cell carcinoma (RCC) is a malignancy accompanied by a high mortality rate. 3-phosphoinositide-dependent protein kinase 1 (PDK1) has been established as a protein target and generated considerable interest in both the pharmaceutical and academia industry. The aim of the current study was to investigate the effect of si-PDK1 on the RCC cell apoptosis, proliferation, migration, invasion and epithelial mesenchymal transition (EMT) in connection with the PI3K-PDK1-Akt pathway. Microarray analysis from the GEO database was adopted to identify differentially expressed genes (DEGs) related to RCC, after which the positive expression of the PDK1 protein in tissue was determined accordingly. The optimal silencing si-RNA was subsequently selected and RCC cell lines 786-O and A498 were selected and transfected with either a si-PDK1 or activator of the PI3K-PDK1-Akt pathway for grouping purposes. The mRNA and protein expressions of PDK1, the PI3K-PDK1-Akt pathway-, EMT- and apoptosis-related genes were then evaluated. The effect of si-PDK1 on cell proliferation, apoptosis, invasion and migration was then analyzed. Through microarray analysis of GSE6344, GSE53757, GSE14762 and GSE781, PDK1 was examined. PDK1 was determined to be highly expressed in RCC tissues. Si-PDK1 exhibited marked reductions in relation to the mRNA and protein expression of PDK1, PI3K, AKT as well as Vimentin while elevated mRNA and protein expressions of E-cadherin were detected, which ultimately suggested that cell migration, proliferation and invasion had been inhibited coupled with enhanced levels of cell apoptosis. While a notable observation was made highlighting that the PI3K-PDK1-Akt pathway antagonized the effect of PDK1 silencing. Taken together, the key observations of this study provide evidence suggesting that high expressions of PDK1 are found in RCC, while highlighting that silencing PDK1 could inhibit RCC cell proliferation, migration, invasion and EMT by repressing the PI3K-PDK1-Akt pathway.

Identifiants

pubmed: 30465826
pii: S0898-6568(18)30286-9
doi: 10.1016/j.cellsig.2018.11.016
pii:
doi:

Substances chimiques

Antigens, CD 0
CDH1 protein, human 0
Cadherins 0
RNA, Small Interfering 0
Vimentin 0
3-Phosphoinositide-Dependent Protein Kinases EC 2.7.11.1
PDPK1 protein, human EC 2.7.11.1
Proto-Oncogene Proteins c-akt EC 2.7.11.1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-14

Informations de copyright

Copyright © 2018. Published by Elsevier Inc.

Auteurs

Wei-Min Zhou (WM)

Jiangxi Medical College, Nanchang University, Nanchang 330006, PR China; Department of Urology, Jiangxi Cancer Hospital, Nanchang 330029, PR China.

Gao-Liang Wu (GL)

Department of Urology, Jiangxi Cancer Hospital, Nanchang 330029, PR China.

Ji Huang (J)

Department of Urology, Jiangxi Cancer Hospital, Nanchang 330029, PR China.

Jin-Gao Li (JG)

Department of Radiotherapy, Jiangxi Cancer Hospital, Nanchang 330029, PR China.

Chao Hao (C)

Department of Urology, Jiangxi Cancer Hospital, Nanchang 330029, PR China.

Qiu-Ming He (QM)

Department of Urology, Jiangxi Cancer Hospital, Nanchang 330029, PR China.

Xiao-Dan Chen (XD)

Department of Science and Education, Jiangxi Cancer Hospital, Nanchang 330029, PR China.

Gong-Xian Wang (GX)

Jiangxi Medical College, Nanchang University, Nanchang 330006, PR China; Department of Urology, The First Affiliated Hospital of Nanchang University, Nanchang 330006, PR China. Electronic address: gongxianwang118@163.com.

Xin-Hua Tu (XH)

Department of Urology, Jiangxi Cancer Hospital, Nanchang 330029, PR China. Electronic address: tu_xinhua@126.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH